| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5365 | 2012 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3493 | 2014 |
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study K Fizazi, M Carducci, M Smith, R Damião, J Brown, L Karsh, P Milecki, ... The Lancet 377 (9768), 813-822, 2011 | 2391 | 2011 |
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a … ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ... The lancet oncology 15 (7), 700-712, 2014 | 1629 | 2014 |
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer … DH Henry, L Costa, F Goldwasser, V Hirsh, V Hungria, J Prausova, ... Journal of Clinical Oncology 29 (9), 1125-1132, 2011 | 1455 | 2011 |
| Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome KE Nichols, DP Harkin, S Levitz, M Krainer, KA Kolquist, C Genovese, ... Proceedings of the National Academy of Sciences 95 (23), 13765-13770, 1998 | 584 | 1998 |
| Germ-Line BRCA1 Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer MG FitzGerald, DJ MacDonald, M Krainer, I Hoover, E O'Neil, H Unsal, ... New England Journal of Medicine 334 (3), 143-149, 1996 | 509 | 1996 |
| Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families P Tonin, B Weber, K Offit, F Couch, TR Rebbeck, S Neuhausen, ... Nature medicine 2 (11), 1179-1183, 1996 | 396 | 1996 |
| Differential Contributions of BRCA1 and BRCA2 to Early-Onset Breast Cancer M Krainer, S Silva-Arrieta, MG FitzGerald, A Shimada, C Ishioka, ... New England journal of medicine 336 (20), 1416-1422, 1997 | 315 | 1997 |
| Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1 M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ... Journal of Clinical Oncology 34 (25), 3005-3013, 2016 | 249 | 2016 |
| Third consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ... Annals of oncology 20 (11), 1771-1785, 2009 | 241 | 2009 |
| Interleukin-6 is a prognostic factor in multiple myeloma [letter][see comments] H Ludwig, DM Nachbaur, E Fritz, M Krainer, H Huber | 212 | 1991 |
| Monitoring of Serum Her-2/neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer WJ Köstler, B Schwab, CF Singer, R Neumann, E Rücklinger, ... Clinical cancer research 10 (5), 1618-1624, 2004 | 204 | 2004 |
| Contribution of epigenetic silencing of tumor necrosis factor–related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer P Horak, D Pils, G Haller, I Pribill, M Roessler, S Tomek, R Horvat, ... Molecular cancer research 3 (6), 335-343, 2005 | 185 | 2005 |
| Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients E Obermayr, F Sanchez-Cabo, MKM Tea, CF Singer, M Krainer, ... BMC cancer 10, 1-12, 2010 | 156 | 2010 |
| HIF1α regulates mTOR signaling and viability of prostate cancer stem cells M Marhold, E Tomasich, A El-Gazzar, G Heller, A Spittler, R Horvat, ... Molecular Cancer Research 13 (3), 556-564, 2015 | 153 | 2015 |
| Second consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, ... Annals of oncology 18 (2), 215-225, 2007 | 151 | 2007 |
| Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of … K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, ... European urology 78 (6), 822-830, 2020 | 146 | 2020 |
| Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors H Ludwig, E Fritz, C Leitgeb, M Krainer, I Kührer, P Sagaster, H Umek Annals of oncology 4 (2), 161-167, 1993 | 131 | 1993 |
| In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway D Pils, A Pinter, J Reibenwein, A Alfanz, P Horak, BC Schmid, L Hefler, ... British journal of cancer 96 (3), 485-491, 2007 | 125 | 2007 |
Robert ZeillingerProfessor of Tumor BiologyVerified email at muv.ac.at
